Hematology

The new MonumenTAL-6 combination data appear to exceed MajesTEC-9 numbers.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

These results provide support for a potential new standard of care in the relapsed/refractory setting.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.

This analysis, presented by Rahul Banerjee, MD, FACP, at EHA 2026, builds on data that supported the FDA’s March 2026 approval of teclistamab.

Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.

Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).

The senior director of the Clinical Trial Support Center at Blood Cancer United explains how nurse navigators help patients reach a 20% trial enrollment rate.

Karilyn Larkin, MD, traces her equity focus to her medically underserved hometown, urging new diagnostics, trial design, and honest patient talks to close AML gaps.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting disease-modifying potential.

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions.

As presented at EHA 2026, AGAVE-201 showed no significant bone health safety signals with axatilimab in chronic graft-versus-host disease (cGVHD).

Ajai Chari, MD, addresses myeloma’s future: personalized care, shared decision-making, and why striving for a functional cure matters now.

Kerry Rogers, MD, discusses financial toxicity, equitable access to BTK inhibitors, and how frailty shapes CLL clinical trial design.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.

FDA approves Orca-T precision Treg cell therapy for matched donor transplants, cutting chronic GVHD risk and boosting survival in blood cancers.